Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01610 in Relapsed Small Cell Lung Cancer
CTR20200453Phase 2Completed
- Sponsor
- Luye Pharma Group
- Start
- Mar 2020
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in small cell lung cancer (SCLC), sponsored by Luye Pharma Group. Started Mar 2020; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20200453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200453.